Cargando…
Activation of Lipid Mediator Formation Due to Lipoprotein Apheresis
Lipoprotein apheresis reliably reduces low-density lipoprotein (LDL) cholesterol in patients with atherosclerotic disease and therapy-refractory hypercholesterolemia or elevated lipoprotein (a) (Lp(a)). Besides lowering lipoproteins and triglycerides, apheresis also decreases levels of essential ome...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412478/ https://www.ncbi.nlm.nih.gov/pubmed/30744123 http://dx.doi.org/10.3390/nu11020363 |
_version_ | 1783402614475456512 |
---|---|
author | Weylandt, Karsten-H. Schmöcker, Christoph Ostermann, Annika I. Kutzner, Laura Willenberg, Ina Kiesler, Stefanie Steinhagen-Thiessen, Elisabeth Schebb, Nils Helge Kassner, Ursula |
author_facet | Weylandt, Karsten-H. Schmöcker, Christoph Ostermann, Annika I. Kutzner, Laura Willenberg, Ina Kiesler, Stefanie Steinhagen-Thiessen, Elisabeth Schebb, Nils Helge Kassner, Ursula |
author_sort | Weylandt, Karsten-H. |
collection | PubMed |
description | Lipoprotein apheresis reliably reduces low-density lipoprotein (LDL) cholesterol in patients with atherosclerotic disease and therapy-refractory hypercholesterolemia or elevated lipoprotein (a) (Lp(a)). Besides lowering lipoproteins and triglycerides, apheresis also decreases levels of essential omega-6 and omega-3 polyunsaturated fatty acids (n-6 and n-3 PUFAs) in blood plasma. In contrast, heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) lipid apheresis might increase the formation of potentially pro-inflammatory and pro-thrombotic lipid mediators derived from n-6 and n-3 PUFAs. The study presented here analyzed lipid mediator profiles in the plasma of patients with hyperlipidemia treated by one of three different apheresis methods, either HELP, direct absorption (DA), or membrane filtration (MDF), in a direct pre- and post-apheresis comparison. Using gas chromatography and liquid chromatography tandem mass spectrometry (LC-MS/MS) we were able to analyze fatty acid composition and the formation of lipid mediators called oxylipins. Our data illustrate—particularly in HELP-treated patients—significant decreases of essential omega-6 and omega-3 polyunsaturated fatty acids in blood plasma but significant increases of PUFA-derived lipoxygenase-, as well as cyclooxygenase- and cytochrome P450-derived lipid mediators. Given that n-3 PUFAs in particular are presumed to be cardioprotective and n-3 PUFA-derived lipid mediators might limit inflammatory reactions, these data indicate that n-3 PUFA supplementation in the context of lipid apheresis treatment might have additional benefits through apheresis-triggered protective n-3 PUFA-derived lipid mediators. |
format | Online Article Text |
id | pubmed-6412478 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64124782019-03-29 Activation of Lipid Mediator Formation Due to Lipoprotein Apheresis Weylandt, Karsten-H. Schmöcker, Christoph Ostermann, Annika I. Kutzner, Laura Willenberg, Ina Kiesler, Stefanie Steinhagen-Thiessen, Elisabeth Schebb, Nils Helge Kassner, Ursula Nutrients Article Lipoprotein apheresis reliably reduces low-density lipoprotein (LDL) cholesterol in patients with atherosclerotic disease and therapy-refractory hypercholesterolemia or elevated lipoprotein (a) (Lp(a)). Besides lowering lipoproteins and triglycerides, apheresis also decreases levels of essential omega-6 and omega-3 polyunsaturated fatty acids (n-6 and n-3 PUFAs) in blood plasma. In contrast, heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) lipid apheresis might increase the formation of potentially pro-inflammatory and pro-thrombotic lipid mediators derived from n-6 and n-3 PUFAs. The study presented here analyzed lipid mediator profiles in the plasma of patients with hyperlipidemia treated by one of three different apheresis methods, either HELP, direct absorption (DA), or membrane filtration (MDF), in a direct pre- and post-apheresis comparison. Using gas chromatography and liquid chromatography tandem mass spectrometry (LC-MS/MS) we were able to analyze fatty acid composition and the formation of lipid mediators called oxylipins. Our data illustrate—particularly in HELP-treated patients—significant decreases of essential omega-6 and omega-3 polyunsaturated fatty acids in blood plasma but significant increases of PUFA-derived lipoxygenase-, as well as cyclooxygenase- and cytochrome P450-derived lipid mediators. Given that n-3 PUFAs in particular are presumed to be cardioprotective and n-3 PUFA-derived lipid mediators might limit inflammatory reactions, these data indicate that n-3 PUFA supplementation in the context of lipid apheresis treatment might have additional benefits through apheresis-triggered protective n-3 PUFA-derived lipid mediators. MDPI 2019-02-09 /pmc/articles/PMC6412478/ /pubmed/30744123 http://dx.doi.org/10.3390/nu11020363 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Weylandt, Karsten-H. Schmöcker, Christoph Ostermann, Annika I. Kutzner, Laura Willenberg, Ina Kiesler, Stefanie Steinhagen-Thiessen, Elisabeth Schebb, Nils Helge Kassner, Ursula Activation of Lipid Mediator Formation Due to Lipoprotein Apheresis |
title | Activation of Lipid Mediator Formation Due to Lipoprotein Apheresis |
title_full | Activation of Lipid Mediator Formation Due to Lipoprotein Apheresis |
title_fullStr | Activation of Lipid Mediator Formation Due to Lipoprotein Apheresis |
title_full_unstemmed | Activation of Lipid Mediator Formation Due to Lipoprotein Apheresis |
title_short | Activation of Lipid Mediator Formation Due to Lipoprotein Apheresis |
title_sort | activation of lipid mediator formation due to lipoprotein apheresis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412478/ https://www.ncbi.nlm.nih.gov/pubmed/30744123 http://dx.doi.org/10.3390/nu11020363 |
work_keys_str_mv | AT weylandtkarstenh activationoflipidmediatorformationduetolipoproteinapheresis AT schmockerchristoph activationoflipidmediatorformationduetolipoproteinapheresis AT ostermannannikai activationoflipidmediatorformationduetolipoproteinapheresis AT kutznerlaura activationoflipidmediatorformationduetolipoproteinapheresis AT willenbergina activationoflipidmediatorformationduetolipoproteinapheresis AT kieslerstefanie activationoflipidmediatorformationduetolipoproteinapheresis AT steinhagenthiessenelisabeth activationoflipidmediatorformationduetolipoproteinapheresis AT schebbnilshelge activationoflipidmediatorformationduetolipoproteinapheresis AT kassnerursula activationoflipidmediatorformationduetolipoproteinapheresis |